ENG - Metalgial PDF

USER INFORMATION PAMPHLET
Metalgial 500mg/ml oral drops in solution

(sodium metamizole)
Read the whole of this prospectus in detail, because it contains information that will be
important to you.
This medication can be obtained without a prescription for the treatment of minor afflictions
without the intervention of a doctor. However, you must use Metalgial with care to obtain
the best results.
-Keep this prospectus; you may need to read it again.
-If you have any doubts, consult your doctor or pharmacists.
This medicine has been prescribed to you and must not be given to others. It may harm
them, even when their symptoms are the same as yours.
In this prospectus:
1. What are Metalgial and what are they used for?
2. Before using Metalgial
3. How to use Metalgial
4. Possible adverse effects
5. Storage of Metalgial
1.WHAT IS METALGIAL AND WHAT IS IT USED FOR?

Metamizole, the principal ingredient of Metalgial 500mg/ml oral drops in solution, is a
analgesic and antipyretic medicine for the treatment of pain and fever. It belongs to the
pyrazalone group of medicines.
Metalgial 500mg/ml oral drops in solution is used in the treatment of acute post
operation or post trauma pain, colic pain or pain originating from a tumour. It is also
used in cases of high temperatures which do not respond to other antithermics.
2.BEFORE TAKING METALGIAL
Do not take Metalgial:

- If your doctor has not prescribed this medicine.
- If you have a history of hyper sensibility (allergy) to metamizole or any
other pyrazolonic derivatives or any of the other components of this
medicine.
- If you have reacted with a decrease in the number of white blood cells
(agranulocytosis) after using these substances.
- If you have had symptoms of asthma, rhinitis or hives (red rashes or wheals
on the skin which can itch) after the administration of asperin, paracetomol
or anti inflammatories, not steroids, as you may be predisposed to be
sensible to metamizole (crossed sensibility).
- If your doctor has diagnosed you with intermittent acute porphyria (a
disorder of the blood pigments metabolism which form part of the
haemoglobin).
- If your doctor has diagnosed a congenital deficiency of dehydrogenated
glucose-6-phosphate (a lack of a protein present in the red blood cells which
can cause a type of anaemia known as hemolytic anaemia).
- If you have suffered alterations of the functioning of bone marrow, for
example after receiving chemotherapy, or if you have had blood illnesses.
Be especially careful with Metalgial

- If you present dizziness, breathing difficulty, rhinitis, facial swelling
(angyneurotic edema), decrease in blood pressure, the sudden apparition of
red stains on the skin, you must suspend the treatment and consult your
doctor immediately, as it could be the sign of a serious allergic reaction
(anaphylaxis/anaphylactic shock).
- If during the treatment you have a high temperature, shivers, sore throat
inflammation in the mouth, nose or throat, injuries in the oral or genital
mucosa you must suspend the treatment and consult your doctor
immediately as this could indicate a decrease in the number of white blood
cells (agranulocytosis).
- If you have had an allergic reaction to metamizole, you must not take
medicine with it again.
- If you suffer asthma syndrome due to painkillers, bronquial asthma,
especially with rinosinusitis and nasal polyps, chronic hives, or if you are
intolerant to colouring agents and/or preservatives or alcohol, as the risk of
possible serious allergic reactions is greater.
- If you have pre existing problems of low blood pressure (below 100mmHg)
or have unstable circulation or present a high temperature as the risk of a
sharp drop in blood pressure is greater.
- If you have a diminished hepatic or renal function.
Use of other medicines

Inform your doctor or pharmacist if you are using or have recently used other medicines
including those acquired without prescription.
If you administer metamizole in conjunction with cyclosporine, you can reduce the
levels of cyclosporine in the blood, as such these need to be measured regularly.
Taking Metalgial with food and drink:

Combined with alcohol the effects of both substances may be increased.
Pregnancy and while breast feeding:

Consult your doctor or chemist before taking any medicine.
It is recommended not to administer the medicine during the first and last trimester of
pregnancy. In the second trimester it shall only be used once the doctor has weighed up
the benefit/risk balance.
The metalobites of metamizole are excreted with maternal milk, as such breast feeding
must be avoided for the 48 hours following its administration.
Driving and the use of machines:
Although adverse effects on the capacity to concentrate and react are not expected, with
higher doses, among those recommended, it should be born in mind that these capacities
could be affected and the use of machines, driving and other dangerous activities should
be avoided. This is particularly true when alcohol has been consumed.
Important information about some of the components of Metalgial:

Patients with low sodium diets must bear in mind that this medicine contains 35 mg (1.5
mmol) of sodium per ml (20 drops).
3.How to take Metalgial
Follow the administration instructions given by your doctor exactly. Consult your
doctor or chemist if you have doubts.
If you consider that the effect of Metalgial is too strong or weak, communicate this to
your doctor or chemist.
This medicine must be administered orally. The habitual dose is:
• Adults and teenagers older than 15: 500 mg (20 drops), 3 or 4 times a day.
• Children between 5 and 14: 10-15 drops up to 4 times a day.
• Children breast feeding over 4 months old up to 4 year olds: 2-6 drops up to 4
times a day.
A clear therapeutic benefit can be expected 30 to 60 minutes after administration. Your

doctor will indicate the duration of your treatment with Metalgial.
Dosage in those with renal or hepatic insufficiency:

In patients with a diminished renal or hepatic function, as with elderly patients or those
with a generally diminished condition, the administration of high doses should be
avoided.
Instructions for the correct administration of the product:

The drops are administered orally with a little water.
1.To extract the jar’s security lid, press on its surface (A) while at the same time
unscrewing in an anticlockwise direction (B).
2.Once the top has been extracted place the jar in a vertical and totally inverted position.
DO NOT SHAKE. WAIT A FEW SECONDS UNTIL THE FIRST DROP COMES
OUT.
If you take more Metalgial than you should:
Nausea, vomiting, abdominal pain and deterioration of the renal function could appear,
and in very rare cases, vertigo, drowsiness, coma, convulsions and decreased blood
pressure.
After the administration of very high doses of metamizole a red colouration of urine
may occur, this disappears on suspension of the treatment.
In the case of overdose or accidental ingestion, immediately consult your doctor or
chemist, or the Toxicology Information Service, telephone: 915620420.
If you forget to take Metalgial:

Do not take a double dose to compensate those missed.
If you have any other doubt about the use of this product, ask your doctor or chemist.
4.POSSIBLE SIDE EFFECTS
As with all medicines, Metalgial can produce side effects, although not everyone suffers
from them.
Infrequent side effects, which affect between 1 and 10 of every 1000 people.
-Drug induced rashes

-Decrease in blood pressure
Rare side effects, which affect between 1 and 10 of every 10000 patients.
-The weakest allergic reactions habitually manifest themselves as skin and mucosa
symptoms (for example, itching, burning, reddening, hives, swelling), breathing
difficulty, and with less frequency gastrointestinal disturbances. These weak reactions
can progress till they are serious. In patients with asthmatic symptoms caused by
painkillers, these reactions of intolerance habitually manifest themselves as asthma
attacks.
-Skin rashes
-Decrease in the number of white blood cells (leucopoenia).
Very rare side effects, which affect less than 1 every 10000 people.
-Serious allergic reactions which can appear with generalised hives, swelling of feet,
hands, lips, throat and respiratory paths (angyoedema), decrease in the passing of air to
the lungs due to the sharp closure of the bronchi, alterations of the cardiac rhythm,
decreased blood pressure (sometimes preceded by an increase in blood pressure) and
circulatory crash, which can put your life at risk. These reactions can appear even if you
have already taken metamizole on other occasions without complications and usually
appear in the first hour following administration.
-Very serious cutaneous blistering reactions (Stevens-Johnson syndrome or Lyell’s
syndrome).
-Decrease in the number of platelets in the blood (thrombocytopenia).
-Serious decrease in the number of white blood cells (agranulocytosis).
-Alteration in the functioning of the kidneys with a decrease or suppression of the
quantity of urine, increase in the elimination of proteins in the urine and/or kidney
inflammation (sharp interstitial nephritis).
If you consider any of the side effects you are suffering to be serious, or if you
appreciate any other adverse effect not mentioned in this pamphlet, inform your doctor
or pharmacist.
5.Conservation of Metalgial
Keep out of sight and reach of children.
It does not require special conservation conditions.
Do not use Metalgial after the expiry date which appears on the container after CAD,
The expiry date is the last day of the month indicated.
Medicines must not be disposed of in the drains or thrown away. Leave unwanted
medicines and containers at the SIGRE point in a chemist. Ask your pharmacist how to
dispose of any containers or unneeded medicines. This way you will help look after the
environment.
6.Additional information
Composition of Metalgial
The principal ingredient is sodium metamizole. Each ml (20 drops) of solution contains
500mg of sodium metamizole, which is equivalent to 467.3mg of metamizole.
The other components are: dibasic dodecahydrate sodium phosphate, dehydrated
sodium phosphate, purified water, aroma of raspberry and sodium saccharin.
Product appearance and container contents

Metalgial 500mg/ml is presented as an oral solution. Each container contains 20ml of
solution and a medicine dropper.
Holder of the authorisation and responsible for fabrication of the product.
Holder of the authorisation

LABORATORIOS ERN, S.A.
C/ Pedro IV, 499
08020 Barcelona
España
Producer
ABC Farmaceutici S.p.A.
Canton Moretti 29 – Loc. S. Bernardo
10090 Ivrea (TO) – ITALIA
This product was approved in April 2010.

Detailed and updated information about this product is available on the webpage of the
Spanish Agency for Medicines and Health Products (AEMPS)
http://www.aemps.gob.es/

ENG - Metalgial PDF

Uploaded by

Copyright:

Available Formats

ENG - Metalgial PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ENG - Metalgial PDF

Uploaded by

Copyright:

Available Formats

USER INFORMATION PAMPHLET

Metalgial 500mg/ml oral drops in solution

1.WHAT IS METALGIAL AND WHAT IS IT USED FOR?

2.BEFORE TAKING METALGIAL

Do not take Metalgial:

Be especially careful with Metalgial

Use of other medicines

Taking Metalgial with food and drink:

Pregnancy and while breast feeding:

Important information about some of the components of Metalgial:

3.How to take Metalgial

This medicine must be administered orally. The habitual dose is:

A clear therapeutic benefit can be expected 30 to 60 minutes after administration. Your

Dosage in those with renal or hepatic insufficiency:

Instructions for the correct administration of the product:

If you forget to take Metalgial:

4.POSSIBLE SIDE EFFECTS

-Drug induced rashes

Keep out of sight and reach of children.

It does not require special conservation conditions.

Product appearance and container contents

Holder of the authorisation and responsible for fabrication of the product.

Holder of the authorisation

This product was approved in April 2010.

You might also like